We’re thrilled to announce that on October 3, 2024, Bioptic entered into a strategic partnership with eMolecules, a leading provider of chemical sourcing solutions. This collaboration integrates eMolecules’ extensive chemical space of over 20 million compounds into Bioptic’s AI-driven platform, empowering scientists with instant compound screening and seamless ordering capabilities. In this blog post, we explore how this partnership enhances our mission to accelerate drug discovery and bring life-saving therapies to patients faster.
A Powerful Integration for Drug Discovery
The partnership with eMolecules combines Bioptic’s advanced AI technology with eMolecules’ vast chemical library, creating a seamless workflow for researchers. Bioptic’s platform, which uses AI models like SMILES-based large language models and graph neural networks, can now instantly screen eMolecules’ database of over 20 million compounds to identify promising drug candidates. Once identified, scientists can order these compounds directly through eMolecules’ efficient procurement system, streamlining the transition from virtual screening to laboratory validation.
This integration addresses a critical bottleneck in drug discovery: the time and complexity of sourcing high-quality compounds. By combining Bioptic’s rapid screening capabilities with eMolecules’ reliable supply chain, researchers can significantly reduce the time it takes to move from discovery to development, ultimately accelerating drugs’ time to market.
What This Means for Bioptic and the Industry
This collaboration enhances Bioptic’s ability to deliver on our mission of revolutionizing drug discovery through AI. By leveraging eMolecules’ chemical space, we can explore a broader range of potential drug candidates, including those for challenging targets like the “undruggable” proteins in cancer, as seen in our recent $17.5 million deal with Vindur Tx. The partnership also aligns with industry trends, where AI-driven drug discovery is gaining momentum for its ability to cut costs and timelines, as noted in recent analyses of the pharmaceutical sector.
For the broader biotech community, this partnership sets a new standard for efficiency in drug discovery workflows. It empowers scientists to focus on innovation rather than logistics, fostering faster development of therapies that address unmet medical needs.
Looking Ahead
The collaboration with eMolecules marks a significant step forward for Bioptic as we continue to build tools that transform drug discovery. We’re excited to see the impact of this partnership on our ongoing projects, such as our work on selective kinase inhibitors, and look forward to empowering researchers worldwide with these enhanced capabilities.
